Targeting PLCG2 Suppresses Tumor Progression, Orchestrates the Tumor Immune Microenvironment and Potentiates Immune Checkpoint Blockade Therapy for Colorectal Cancer.

While the AUC values did not show a decreasing trend with increasing survival time, PLCG2 remained a valuable prognostic marker with satisfactory performance across the predicted time points ( Figure S2 E).

also in 47,180 other papers